WASHINGTON (dpa-AFX) - Shares of Seattle Genetics (SGEN) have climbed well off their worst levels but continue to see notable weakness in late-day trading on Monday. After hitting a four-month intraday low, Seattle Genetics is currently down by 3.7 percent.
The initial drop by Seattle Genetics came after the biotechnology company said it is halting a late-stage trial of trial of vadastuximab talirine in frontline older acute myeloid leukemia patients.
Copyright RTT News/dpa-AFX